Tracy Doll
Optometrist · Portland, ORNPI 1700991916
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (58.2%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 17 manufacturers reported payments, led by Sun Pharmaceutical Industries Inc. at 41.0% of the total. 2025 is the largest year on record at $41,731, 2.0 times the $20,546 reported in 2019. Among optometrist clinicians in OR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 321 payments — averaging $511.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sun Pharmaceutical Industries Inc.$67K
- Bausch & Lomb Americas Inc.$35K
- Biotissue Holdings Inc.$25K
- Shire North American Group Inc$15K
- Novartis$6K
- Alcon$6K
- plus $10K from 11 others
What the payments were for
- Consulting fees$29,99018%
- Speaking & faculty fees$95,53058%
- Travel & lodging$28,39517%
- Food & beverage$10,0916%
- Education$360%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sun Pharmaceutical Industries Inc. | 95 | $67,337 |
| Bausch & Lomb Americas Inc. | 92 | $35,173 |
| Biotissue Holdings Inc. | 36 | $24,606 |
| Shire North American Group Inc | 23 | $15,479 |
| Novartis | 13 | $5,670 |
| Alcon | 12 | $5,613 |
| Tarsus Pharmaceuticals, Inc. | 9 | $2,450 |
| Alcon Research LLC | 1 | $2,400 |
| Kala Pharmaceuticals, Inc. | 3 | $1,754 |
| AbbVie(2 entities) | 11 | $1,420 |
| Oyster Point Pharma, Inc. | 6 | $1,069 |
| Carl Zeiss Meditec USA, Inc. | 8 | $491 |
| Sight Sciences, Inc. | 4 | $241 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $121 |
| ANI Pharmaceuticals, Inc. | 3 | $107 |
| Dompe US, Inc. | 2 | $93 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CEQUA$66,299
- XIIDRA$48,178
- MIEBO$31,774
- Prokera$7,978
- TRYPTYR$6,918
- AmnioGraft$5,790
- AmnioGuard$2,643
- EYSUVIS$1,710
- XDEMVY$1,146
- LUMIGAN$1,021
- DAILIES$957
- TYRVAYA$840
- ALPHAGAN P$756
- COMBIGAN$756
- AIR OPTIX$648
- BLINK NUTRITEARS$500
- CIRRUS HD-OCT$413
- LOTEMAX SM$272
- TearCare$165
- VYZULTA$157
How this compares
$164,041 in reported general payments places this provider in the 95th percentile of 684 optometrist providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MieboPerfluorohexyloctane/Pf | 34 | $30,226 |
| XdemvyLotilaner | 12 | $22,898 |
| RestasisCyclosporine | 17 | $21,418 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb Americas Inc.Miebo | $35,173 | $30,22634 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $2,450 | $22,89812 claims |
| AbbVieRestasis | $1,420 | $21,41817 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 684 optometrist providers in Oregon.
Other optometrist in Portland
- Roger TabbPortland$239K
- Mila IoussifovaPortland$223K
- Blair LonsberryPortland$76K
- Sagina O'HalloranPortland$7K
- Thomas BarretoPortland$6K
- Laura ArmstrongPortland$5K
- Marc SchmittPortland$5K
- Carole TongPortland$3K
- Johnny DuongPortland$3K
- Kevie KawasakiPortland$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.